Structure Therapeutics Financials
| GPCR Stock | 19.94 0.06 0.30% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 25.98 | 24.7414 |
|
|
The financial analysis of Structure Therapeutics is a critical element in measuring its lifeblood. Investors should not minimize Structure Therapeutics' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Structure | Select Account or Indicator |
Understanding current and past Structure Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Structure Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Structure Therapeutics' assets may result in an increase in income on the income statement.
Structure Therapeutics Stock Summary
Structure Therapeutics competes with Day One, Mirum Pharmaceuticals, Rocket Pharmaceuticals, Avidity Biosciences, and Uniqure NV. Structure Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| CUSIP | 86366E106 |
| Location | California; U.S.A |
| Business Address | 601 Gateway Boulevard, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | structuretx.com |
| Phone | 650 457 1978 |
Structure Therapeutics Key Financial Ratios
| Return On Equity | -0.19 | ||||
| EBITDA | (158.23 M) | ||||
| Net Income | (122.53 M) | ||||
| Book Value Per Share | 15.10 X | ||||
| Market Capitalization | 1.15 B |
Structure Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Structure Therapeutics's current stock value. Our valuation model uses many indicators to compare Structure Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Structure Therapeutics competition to find correlations between indicators driving Structure Therapeutics's intrinsic value. More Info.Structure Therapeutics American is rated # 3 in return on equity category among its peers. It is rated # 4 in return on asset category among its peers . At this time, Structure Therapeutics' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Structure Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Structure Therapeutics Systematic Risk
Structure Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Structure Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Structure Therapeutics correlated with the market. If Beta is less than 0 Structure Therapeutics generally moves in the opposite direction as compared to the market. If Structure Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Structure Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Structure Therapeutics is generally in the same direction as the market. If Beta > 1 Structure Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Structure Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Structure Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Structure Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Structure Therapeutics March 28, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Structure Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Structure Therapeutics American. We use our internally-developed statistical techniques to arrive at the intrinsic value of Structure Therapeutics American based on widely used predictive technical indicators. In general, we focus on analyzing Structure Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Structure Therapeutics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.10) | |||
| Maximum Drawdown | 25.66 | |||
| Value At Risk | (8.73) | |||
| Potential Upside | 5.95 |
Additional Tools for Structure Stock Analysis
When running Structure Therapeutics' price analysis, check to measure Structure Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Structure Therapeutics is operating at the current time. Most of Structure Therapeutics' value examination focuses on studying past and present price action to predict the probability of Structure Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Structure Therapeutics' price. Additionally, you may evaluate how the addition of Structure Therapeutics to your portfolios can decrease your overall portfolio volatility.